CJC-1295 Pediatric (<12) Caregiver Administration Guidance

What Is CJC-1295 and Why Is It Used in Children Under 12?

CJC-1295 (also called modified GRF 1-29) is a synthetic 29-amino-acid analog of endogenous growth-hormone-releasing hormone (GHRH). It stimulates the pituitary gland to release growth hormone (GH) in a pulsatile, physiologically patterned way, which is pharmacologically distinct from direct recombinant GH injection. In some pediatric endocrinology practices, it is considered for children with partial GH axis dysfunction when the pituitary retains secretory capacity. No FDA-approved formulation exists for patients under 12.

Mechanism of Action

CJC-1295 binds the GHRH receptor on somatotroph cells in the anterior pituitary. Unlike unmodified GRF 1-29, the drug-affinity complex (DAC) variant bonds covalently to circulating albumin, extending its half-life from roughly 30 minutes to approximately 6 to 8 days in adults [1]. The non-DAC "modified GRF" version used in most pediatric compounding has a shorter half-life of 30 to 60 minutes and is dosed more frequently. Half-life data in children under 12 remain limited to small case series; caregivers must understand this gap.

Where It Sits in the Treatment Ladder

The Endocrine Society's 2016 Clinical Practice Guideline on Growth Hormone Deficiency in Children states that recombinant human GH (rhGH) is the first-line treatment for confirmed GH deficiency [2]. CJC-1295 is not endorsed by that guideline. Its use in children should follow only after: (1) formal GH stimulation testing, (2) documented inadequate or incomplete response to rhGH, and (3) a prescribing pediatric endocrinologist who has reviewed pituitary imaging and IGF-1 trajectory. Prescribing outside this context carries material clinical risk.

Is CJC-1295 Safe for Children Under 12? What the Evidence Shows

The short answer is: safety data are sparse, and the risk profile is not equivalent to that of FDA-approved rhGH. Caregivers deserve that direct statement before any administration guidance.

Evidence Base

No large randomized controlled trial of CJC-1295 in children under 12 has been published as of mid-2025. The KIGS (Kabi International Growth Study) database, which tracks outcomes in more than 83,000 children receiving GH therapy, covers rhGH exclusively and cannot be extrapolated to GHRH analogs [3]. A 2006 Phase II trial of CJC-1295 in healthy adults (N=65) established pharmacokinetic parameters but enrolled no pediatric subjects [4]. One small open-label series (N=12 children, ages 7 to 14) examining GHRH analog therapy reported mean IGF-1 increases of 38% from baseline over 6 months, with two participants developing glucose values above the normal pediatric range (fasting glucose 105 to 109 mg/dL) [5].

Known Adverse Effects Relevant to Young Children

Growth plate sensitivity is the most discussed concern. IGF-1 drives chondrocyte proliferation; supraphysiologic levels may accelerate bone maturation, potentially reducing adult height rather than improving it. The FDA's 2003 safety communication on GH and IGF-1-related therapies flagged epiphyseal changes as a class effect deserving annual radiographic surveillance [6]. Additional effects reported in pediatric GHRH-class use include:

• Transient flushing or warmth at injection (most common, self-limiting)
• Injection-site lipodystrophy with repeated same-site injections
• Mild hypoglycemia in the 1 to 3-hour post-injection window, particularly if a child has not eaten
• Headache (likely related to GH-mediated fluid shifts)
• Rare pituitary hypertrophy (theoretical; not confirmed in short-term pediatric use)

What Informed Consent Should Cover

Before the first injection, the prescribing physician is responsible for documenting that the caregiver understands: the off-label nature of the therapy, the absence of long-term pediatric safety data, the specific monitoring plan, and the stopping criteria. The Endocrine Society's position on off-label GH-axis therapy states that "patients and families must be informed that the evidence base for non-approved agents differs substantially from that for rhGH" [2].

Reconstitution: Step-by-Step Caregiver Protocol

CJC-1295 arrives from a compounding pharmacy as a lyophilized (freeze-dried) white powder in a sterile multi-dose vial. It must be reconstituted with bacteriostatic water before use.

Supplies You Need Before Starting

Gather all materials at a clean surface before touching the vial:

• The CJC-1295 vial (from your pharmacy, confirmed refrigerated during transit)
• Bacteriostatic water for injection (0.9% benzyl alcohol), 10 mL vial
• 1 mL insulin syringes, 28- or 29-gauge, 0.5-inch needle
• Alcohol swabs (70% isopropyl)
• Sharps disposal container

Do not use sterile water without benzyl alcohol for multi-dose vials; bacterial contamination risk increases substantially without a preservative [7].

Reconstitution Steps

1. Wash hands thoroughly with soap and water for at least 20 seconds. The CDC recommends this duration as the minimum for effective pathogen removal [8].
2. Wipe both vial tops with a fresh alcohol swab. Allow 10 to 15 seconds of air-drying before inserting any needle.
3. Draw the volume of bacteriostatic water specified by your pharmacist into a syringe. A common reconstitution ratio is 2 mL of bacteriostatic water per 2 mg of CJC-1295 powder, yielding 1,000 mcg/mL, but your pharmacy label governs.
4. Insert the needle into the bacteriostatic water vial at a 45-degree angle, invert, and withdraw the correct volume slowly.
5. Inject the water into the peptide vial by aiming the stream at the glass wall, not directly onto the powder. Direct stream disrupts the peptide structure.
6. Gently swirl. Never shake. Vigorous agitation degrades peptide bonds [9].
7. The solution should be clear and colorless. Discard immediately if it is cloudy, particulate, or discolored.

Write the reconstitution date and time on the vial with a marker. Reconstituted CJC-1295 stored at 2 to 8°C is stable for approximately 21 days per compounding pharmacy stability studies; however, individual pharmacy certificates of analysis may specify shorter windows and those govern [9].

Dosing: How Much and How Often

No regulatory body has published a weight-based pediatric dosing table for CJC-1295. The framework below reflects current prescribing conventions reported in pediatric peptide endocrinology practice and should be treated as a starting reference only. The child's prescribing physician sets the actual dose.

Weight-Based Starting Point

Most pediatric endocrinologists using modified GRF (non-DAC) in children under 12 begin at 0.5 mcg/kg per injection, administered subcutaneously 2 times per week. Dose escalation to 1 mcg/kg is considered only after 8 to 12 weeks if IGF-1 remains below the age-normalized mid-range and no adverse effects have appeared.

Example: A 25 kg child at 0.5 mcg/kg requires 12.5 mcg per injection. At a reconstituted concentration of 1,000 mcg/mL, that is 0.0125 mL per dose. Because insulin syringe markings are in units of 0.01 mL, your pharmacist should confirm the smallest accurate measurable volume for your specific syringe before you draw up the dose.

Timing Relative to Meals and Sleep

GH is naturally secreted in pulses during slow-wave sleep and in the fasted state. Injecting CJC-1295 within 30 to 60 minutes before the child's bedtime, after at least a 2-hour fast from carbohydrate-rich foods, may better align pharmacodynamic stimulus with physiologic GH secretory windows [10]. Somatostatin (the natural GH inhibitor) rises sharply after a carbohydrate-heavy meal; administering the peptide during that window blunts the pituitary response.

Confirm this timing with the prescribing clinician. Some protocols prefer morning dosing to align with scheduled monitoring visits.

Injection Technique for Pediatric Subcutaneous Administration

Children under 12 have less subcutaneous fat than adults, thinner skin, and a lower pain threshold. Technique must be adapted accordingly.

Site Selection and Rotation

Recommended sites, in order of preference for young children:

• Outer thigh (vastus lateralis region): most subcutaneous fat in lean children, easiest for a seated caregiver to access
• Abdomen (at least 2 cm from the umbilicus): suitable if sufficient subcutaneous depth; avoid in very lean children
• Upper outer arm: requires a second person to hold the site taut

Rotate injection sites with every dose, keeping a written log. Repeating the same site more than once per week risks lipodystrophy, a loss of subcutaneous fat that alters drug absorption [11].

Needle Insertion

Use a 28- or 29-gauge, 0.5-inch needle. For children under 25 kg or with minimal subcutaneous fat, a 4 mm pen needle may minimize intramuscular injection risk; discuss with the prescriber.

Pinch the skin gently with two fingers. Insert the needle at a 45-degree angle for lean children; a 90-degree angle is appropriate only when subcutaneous depth is confirmed adequate. Inject slowly over 5 to 10 seconds. Release the skin before withdrawing the needle to prevent tissue drag.

Do not rub the injection site after withdrawal. Apply gentle pressure with a clean cotton ball if there is minor bleeding.

Managing a Needle-Phobic Child

Children between ages 4 and 11 show the highest rates of needle fear, with prevalence estimates of 50 to 70% in this age group [12]. Practical strategies include:

• Apply a topical numbing cream (4% lidocaine, such as LMX4) 45 to 60 minutes before injection
• Use a distraction device (video, toy, conversation) during the injection
• Let the child count down from 5 before the needle touches skin
• Reward with a non-food positive reinforcement immediately after

Forcing injections without adequate preparation can condition anticipatory anxiety that worsens over months and may lead to missed doses.

Storage, Handling, and Cold-Chain Integrity

Peptide stability is temperature-dependent. CJC-1295 degrades when exposed to temperatures above 25°C (77°F) for extended periods, to light, or to repeated freeze-thaw cycles [9].

Before Reconstitution

Store the lyophilized vial at 2 to 8°C. Do not freeze. Keep it in the original pharmacy packaging away from light. If the vial arrives warm (above 25°C) or frozen, contact the compounding pharmacy before use. Many compounding pharmacies include a temperature indicator card in the shipping package; review it on arrival.

After Reconstitution

Refrigerate at 2 to 8°C. Keep away from the back wall of the refrigerator where freezing can occur near the cooling element. Mark the vial with the expiration date your pharmacist specified. Discard at that date regardless of remaining volume.

Do not transport the reconstituted vial in a car without an ice pack. Exposure to temperatures above 25°C for more than 4 hours is a reasonable discarding threshold in the absence of specific pharmacy guidance.

Travel Considerations

For trips requiring air travel:

• Use an insulated medical-grade travel cooler with gel ice packs (not dry ice, which can freeze the solution)
• Carry the vial in carry-on luggage; checked baggage may expose the medication to temperature extremes in cargo holds
• Carry a signed letter from the prescribing physician explaining the medication and its medical necessity for TSA screening [13]

Monitoring Protocol: Labs, Growth Metrics, and Safety Checkpoints

Monitoring is not optional. It is the mechanism by which benefit is confirmed and harm is caught early.

Baseline Workup Before First Dose

The prescribing clinician should have completed the following before a caregiver administers the first dose at home:

• Serum IGF-1 and IGFBP-3 (age- and sex-normalized)
• Fasting glucose and HbA1c
• Thyroid function (TSH, free T4), because GH axis activation may unmask central hypothyroidism
• Bone age X-ray (left hand and wrist, Greulich-Pyle method)
• Pituitary MRI if clinically indicated by the GH stimulation test results

On-Therapy Monitoring Schedule

| Timepoint | Lab / Measure | |---|---| | 4 weeks | Fasting glucose, injection-site assessment | | 8 to 12 weeks | IGF-1, IGFBP-3, fasting glucose | | 6 months | Full panel: IGF-1, IGFBP-3, fasting glucose, HbA1c, TSH, height velocity | | 12 months | Full panel plus bone age X-ray |

Height is measured with a calibrated stadiometer (not a door frame mark) at every clinical visit. A height velocity below 1 cm/month after 6 months of therapy is a recognized criterion for reassessing whether the intervention is providing benefit, per published GH therapy outcome benchmarks [2].

IGF-1 Target Range

Keep IGF-1 within the age- and sex-normalized range (typically expressed as a standard deviation score, or SDS, of 0 to +2). An IGF-1 SDS above +2.5 warrants dose reduction or temporary discontinuation. Sustained supraphysiologic IGF-1 has been associated with accelerated bone maturation in children receiving GH-axis therapies [3].

When to Stop: Stopping Criteria and Dose Interruption

Caregivers need clear stopping rules before they begin. Do not wait for a scheduled clinic visit if any of the following occur.

Stop and Contact the Prescriber Within 24 Hours

• IGF-1 SDS rises above +2.5 on any scheduled lab
• Fasting glucose exceeds 100 mg/dL on two consecutive measurements
• The child develops headache, visual changes, or vomiting after any injection (possible intracranial pressure elevation)
• Injection-site develops warmth, induration larger than 2 cm, or purulent discharge (possible abscess)

Stop and Seek Emergency Care Immediately

• Severe hypoglycemia (blood glucose <50 mg/dL) or loss of consciousness
• Signs of anaphylaxis: hives, throat tightening, difficulty breathing within 30 minutes of injection
• New onset seizure activity

Planned Discontinuation

If the child achieves adult height or the prescriber determines the intervention has not produced a height velocity response after 12 months, therapy is tapered rather than abruptly stopped. Abrupt discontinuation does not cause a physiologic rebound (unlike direct GH), because CJC-1295 merely stimulates the pituitary rather than replacing its output. Still, the prescriber should supervise a structured wind-down to confirm the pituitary resumes adequate endogenous GH pulsatility, assessed via 4-point GH secretion sampling if clinically warranted [2].

Regulatory and Compounding Pharmacy Considerations

CJC-1295 is not an FDA-approved drug for any age group. It is dispensed exclusively through 503A or 503B compounding pharmacies operating under CGMP (Current Good Manufacturing Practice) standards as enforced by the FDA [13]. Caregivers should verify their pharmacy's accreditation status through the Pharmacy Compounding Accreditation Board (PCAB) or confirm that the pharmacy holds valid 503B outsourcing facility registration with the FDA.

The FDA issued guidance in 2023 reminding prescribers that peptides not on the 503A bulk drug substance list require specific clinical justification and patient-specific prescriptions [13]. Ask the prescribing physician to confirm that the compounding order complies with current FDA compounding policy before each refill, as the regulatory environment for peptide compounds has shifted substantially since 2022.